Expanding Options for Treatment of CLL Using BTK Inhibitors

New trial results reveal BGB-16673's promising safety and efficacy in treating relapsed CLL/SLL, showing significant antitumor activity across diverse patient profiles.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with chronic lymphocytic leukemia.